Log in to your account:
Regeneron (REGN), Sanofi Announce FDA Approval of Dupixent for Chronic Rhinosinusitis with Nasal Polyposis
June 26, 2019 1:30 PM
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
June 26, 2019 1:29 PM